Nat Med: A clinical study on the safety and effectiveness of gosuranemab, a monoclonal antibody to Tau protein, in the treatment of progressive supranuclear palsy

Progressive supranuclear palsy (PSP) is a rare, aggressive, rapidly progressing neurodegenerative primary tau disease characterized by physical and cognitive impairment
.
Richardson syndrome is the earliest description of PSP and the most recognized and common form.

At present, neuropathological examination is still the gold standard for diagnosing PSP, which shows abnormal deposition of 4R tau protein in the brainstem, deep cerebellar nucleus, basal ganglia and neocortex
.
These abnormal tau deposits include astrocyte bundles, neurofibrillary tangles, and oligodendrocyte discoids, and are different in PSP phenotypic variants, which are also related to the severity of the disease and other clinical features

Although tau is mainly an intracellular protein, various tau fragments can also be found outside the cell
.
N-terminal tau fragments (ie, tau lacking the microtubule binding region and C-terminal sequence) are particularly abundant in cerebrospinal fluid (CSF)

Gosuranemab (formerly known as BMS-986168 / IPN007 / BIIB092) is a release of neurons against N- terminal tau humanized immune immunoglobulin G4P monoclonal antibodies, found in the intercellular substance (ISF) and CSF
.
Gosuranemab has a high affinity for fibrous tau from patients with PSP and Alzheimer's disease; transgenic mice (rTg4510) take IPN002 (the mouse version of Gosuranemab) every week, and CSF and ISF are detected after 8 weeks.

Recently, researchers conducted a randomized, double-blind, placebo-controlled, 52-week study (number: NCT03068468) to evaluate the clinical effect of gosuranemab in the treatment of progressive supranuclear palsy (PSP)
.

Change from baseline in all PSPRS in 52 weeks (ITT population)

In the study, a total of 486 participants were assigned to the gosuranemab (n = 321) or placebo (n = 165) group
.
At week 52, the adjusted average change in the PSP score table between gosuranemab and placebo (10.

Original source:

Tien Dam et al.